NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









DeuterOncology

DeuterOncology

Private
BelgiumHealthcare & Life Scienceshttps://deuteroncology.com/

Last Round

Grant

Apr 7, 2023

Total Funding Raised

$12.72M

Company Overview

DeuterOncology is a biotechnology company developing a deuterated MET kinase inhibitor as a targeted therapy for MET driven diseases, such as lung cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Precision Medicine, Medical AI

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

MET kinase inhibitornon-small cell lung cancerNSCLCdeuteration technologytargeted cancer therapyclinical stage biotechdeuterated drugoncology drug developmentMET exon 14 skippingsmall molecule drugprecision medicineoral cancer therapyAI drug developmentcompanion diagnostic

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

DeuterOncology Comparables

Compare DeuterOncology with similar companies based on industry and business-model similarity.

DeuterOncology comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Novartis
76%
HUTCHMED (China) Limited
74%
Merck
73%

DeuterOncology Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantApr 7, 2023
Series AJan 19, 2023
Series AJan 19, 2023
SeedFeb 24, 2021

Key People

Founding team and executive leadership

Carol Walton

BD Strategy Advisor To Founder CEO

Founding Team

Els Hubloux

Chief Financial Officer

Executive Team

DeuterOncology Investors

Notable investors and investment history

DeuterOncology investors
InvestorRounds
Public service of WalloniaGrant
Newton BiocapitalSeries A, Seed
NoshaqSeries A
Financière Spin-off LuxembourgeoiseSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Dec 8, 2025

    Monthly visitors increased 677% MoM.

  • Apr 7, 2023

    $515K grant received from Public service of Wallonia.

DeuterOncology Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

DeuterOncology Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about DeuterOncology's valuation, stock price, and market status.

Firmographic Details

HeadquartersBelgium
Employee Range3
Year Founded2020
Last FundingApr 7, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.